Paratek to acquire Optinose and its nasal spray Xhancenews2025-03-20T11:00:54+00:00March 20th, 2025|Endpoints News|
Novartis touts Zolgensma data in older childrennews2025-03-19T19:44:05+00:00March 19th, 2025|Endpoints News|
Gilead stock slips as HHS denies reports of HIV funding cutsnews2025-03-19T18:53:54+00:00March 19th, 2025|Endpoints News|
Ahead of FDA decision, Alnylam faces the big question: Can it make money?news2025-03-19T15:24:19+00:00March 19th, 2025|Endpoints News|
Pfizer fully exits Haleon in $3.3B stake salenews2025-03-19T15:09:05+00:00March 19th, 2025|Endpoints News|
HHS extends administrative leave for probationary workers after court ordernews2025-03-18T18:03:53+00:00March 18th, 2025|Endpoints News|
Sixteen-year-old dies after receiving Sarepta’s Duchenne therapy Elevidysnews2025-03-18T13:21:46+00:00March 18th, 2025|Endpoints News|
Novartis revamps commercial strategy as Entresto patent cliff looms news2025-03-18T11:57:10+00:00March 18th, 2025|Endpoints News|
Trump’s HHS defends Biden-era stance on 340B rebate modelsnews2025-03-17T19:56:43+00:00March 17th, 2025|Endpoints News|
WuXi AppTec’s US revenue growth continues to dip in post-Biosecure environmentnews2025-03-17T18:34:26+00:00March 17th, 2025|Endpoints News|
